Search

Your search keyword '"Oneto R"' showing total 162 results
Start Over Author "Oneto R"
162 results on '"Oneto R"'

1. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation

Author

Martínez, C., Canals, C., Sarina, B., Alessandrino, E.P., Karakasis, D., Pulsoni, A., Sica, S., Trneny, M., Snowden, J.A., Kanfer, E., Milpied, N., Bosi, A., Guidi, S., de Souza, C.A., Willemze, R., Arranz, R., Jebavy, L., Hellmann, A., Sibon, D., Oneto, R., Luan, J.J., Dreger, P., Castagna, L., and Sureda, A.

Published
2013
Full Text
View/download PDF

12. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients

Author

Rambaldi, A, Bacigalupo, A, Fanin, R, Ciceri, F, Bonifazi, F, Falda, M, Lambertenghi-Deliliers, G, Benedetti, F, Bruno, B, Corradini, P, Alessandrino, P E, Iacopino, P, Arcese, W, Scimè, R, Raimondi, R, Sica, S, Castagna, L, Lamparelli, T, Oneto, R, Lombardini, L, Pollichieni, S, Algarotti, A, Carobbio, A, Sacchi, N, and Bosi, A

Published
2012
Full Text
View/download PDF

24. Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?

Author

Giammarco, S, de Latour, Rp, Sica, Simona, Dufour, C, Socie, G, Passweg, J, Kroger, N, Petersen, E, Van Lint, Mt, Oneto, R, Signori, A, Bacigalupo, Andrea, Sica, S (ORCID:0000-0003-2426-3465), Bacigalupo, A (ORCID:0000-0002-9119-567X), Giammarco, S, de Latour, Rp, Sica, Simona, Dufour, C, Socie, G, Passweg, J, Kroger, N, Petersen, E, Van Lint, Mt, Oneto, R, Signori, A, Bacigalupo, Andrea, Sica, S (ORCID:0000-0003-2426-3465), and Bacigalupo, A (ORCID:0000-0002-9119-567X)

Abstract

N/A

Published
2018

25. First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012

Author

Bacigalupo, Andrea, Oneto, R, Schrezenmeier, H, Hochsmann, B, Dufour, C, Kojima, S, Zhu, X, Chen, X, Issaragrisil, S, Chuncharunee, S, Jeong, Dc, Giammarco, Sabrina, Van Lint, Mt, Zheng, Y, Vallejo, C, Bacigalupo Andrea (ORCID:0000-0002-9119-567X), Giammarco S, Bacigalupo, Andrea, Oneto, R, Schrezenmeier, H, Hochsmann, B, Dufour, C, Kojima, S, Zhu, X, Chen, X, Issaragrisil, S, Chuncharunee, S, Jeong, Dc, Giammarco, Sabrina, Van Lint, Mt, Zheng, Y, Vallejo, C, Bacigalupo Andrea (ORCID:0000-0002-9119-567X), and Giammarco S

Abstract

The aim of this study was to assess the outcome of patients with aplastic anemia (AA), receiving rabbit anti-thymocyte globulin (Thymoglobulin, SANOFI) and cyclosporin, as first line treatment. Eligible were 955 patients with AA, treated first line with Thymoglobulin, between 2001 and 2008 (n = 492), or between 2009 and 2012 (n = 463). The median age of the patients was 21 years (range 1-84). Mortality within 90 days was 5.7% and 2.4%, respectively in the two time periods (P = .007).The actuarial 10-year survival for the entire population was 70%; transplant free survival was 64%. Predictors of survival in multivariate analysis, were severity of the disease, patients age and the interval between diagnosis and treatment. Survival was 87% vs 61% for responders at 6 months versus nonresponders (P < .0001). The 10-year survival of nonresponders at 6 months, undergoing a subsequent transplant (n = 110), was 64%, vs 60% for patient not transplantated (n = 266) (P = .1). The cumulative incidence of response was 37%, 52%, 65% respectively, at 90, 180, and 365 days. In multivariate analysis, negative predictors of response at 6 months, were older age, longer interval diagnosis treatment, and greater severity of the disease. In conclusion, early mortality is low after first line treatment of AA with Thymoglobulin, and has been further reduced after year 2008. Patients age, together with interval diagnosis-treament and severity of the disease, remain strong predictors of response and survival

Published
2018

26. Prospective study of rabbit antithymocyte globulin and ciclosporin for aplastic anemia from the EBMT Severe Aplastic Anemia Working Party

Author

Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Passweg JR, Killick SB, Warren AJ, Foukaneli T, Aljurf M, Al Zahrani HA, Schafhausen P, Roth A, Franzke A, Brummendorf TH, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute MO, Mufti GJ, Socie G., RISITANO, ANTONIO MARIA, Marsh, Jc, Bacigalupo, A, Schrezenmeier, H, Tichelli, A, Risitano, ANTONIO MARIA, Passweg, Jr, Killick, Sb, Warren, Aj, Foukaneli, T, Aljurf, M, Al Zahrani, Ha, Schafhausen, P, Roth, A, Franzke, A, Brummendorf, Th, Dufour, C, Oneto, R, Sedgwick, P, Barrois, A, Kordasti, S, Elebute, Mo, Mufti, Gj, and Socie, G.

Published
2012

27. Bone marrow versus peripheral blood sibling transplants in acquired aplastic anemia: survival advantage for marrow in all age groups

Author

Bacigalupo A, Socie' G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuhrer M, Dufour C, Passweg J, Oneto R, Aljurf M, Flynn C, Mialou V, Hamladji RM, Marsh J., RISITANO, ANTONIO MARIA, Bacigalupo, A, Socie', G, Schrezenmeier, H, Tichelli, A, Locasciulli, A, Fuhrer, M, Risitano, ANTONIO MARIA, Dufour, C, Passweg, J, Oneto, R, Aljurf, M, Flynn, C, Mialou, V, Hamladji, Rm, and Marsh, J.

Published
2012

28. Rabbit ATG for aplastic anaemia treatment: a backward step?

Author

European Blood, Marrow Transplant Group, Severe Aplastic Anaemia Working P.a.r.t.y. Dufour C, Bacigalupo A, Oneto R, Socie G, Tichelli A, Passweg JR, Schrezenmeier H, Locasciulli A, Aljurf M, Marsh J.C., RISITANO, ANTONIO MARIA, European, Blood, Marrow Transplant, Group, Dufour C, Severe Aplastic Anaemia Working P. a. r. t. y., Bacigalupo, A, Oneto, R, Socie, G, Tichelli, A, Passweg, Jr, Risitano, ANTONIO MARIA, Schrezenmeier, H, Locasciulli, A, Aljurf, M, and Marsh, J. C.

Subjects
business.industry, Anemia, Aplastic, General Medicine, Prognosis, Molecular biology, Risk Assessment, Sensitivity and Specificity, Severity of Illness Index, Survival Analysis, Treatment Outcome, Cyclosporine, Medicine, Animals, Humans, Rabbits, Rabbit ATG, business, Immunosuppressive Agents, Antilymphocyte Serum, Randomized Controlled Trials as Topic
Published
2011

29. Limited chronic graft-versus-host disease is associated with better survival after alternative donor transplants for haematological malignancies: a retrospective GITMO analysis

Author

Crocchiolo, R., Ciceri, F., Teresa Lamparelli, Oneto, R., Bruno, B., Sormani, M. P., Fanin, R., Bandini, G., Bosi, A., Rambaldi, A., Alessandrino, E., Falda, M., Bacigalupo, A., Crocchiolo, R, Ciceri, Fabio, Lamparelli, T, Oneto, R, Bruno, B, Sormani, Mp, Fanin, R, Bandini, G, Bosi, A, Rambaldi, A, Alessandrino, E, Falda, M, and Bacigalupo, A.

Published
2010

30. HLA-DPB1 T cell epitope 4-group matching is significantly predictive of survival after unrelated hematopoietic stem cell transplantation in onco-hematologic patients from Italy: an updated analysis

Author

Crocchiolo R, Oneto R, Bruno B, Pollichieni S, Sacchi N, Fanin R, Garbarino L, Miotti V, Bandini G, Bosi A, Zino E, Bacigalupo A, Fleischhauer K., CICERI , FABIO, Crocchiolo, R, Oneto, R, Bruno, B, Pollichieni, S, Sacchi, N, Fanin, R, Garbarino, L, Miotti, V, Bandini, G, Bosi, A, Ciceri, Fabio, Zino, E, Bacigalupo, A, and Fleischhauer, K.

Published
2010

31. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation

Author

Crocchiolo, R., Zino, E., Vago, L., Oneto, R., Bruno, B., Pollichieni, S., Sacchi, N., Sormani, M. P., Marcon, J., Lamparelli, T., Fanin, R., Garbarino, L., Miotti, V., Bandini, G., Bosi, A., Ciceri, F., Bacigalupo, A., Fleischhauer, K., Midollo Osseo Gruppo Italiano Trapianto, D. I., Terapia Cellulare, Cellule Staminali Ematopoietiche Cse E., Italian Bone Marrow Donor Registry Collaboratori, Scalari P., Bontempelli, M., Prinoth, O., Carcassi, C., Marceno, R., Porfirio, Rombola, G., Lombardo, Ferrioli, G., Poli, F., Scalamogna, M., Mazzi, B., Rossi, F., Mascaretti, L., Albergoni, Salvaneschi, L., Salvaneschi, M., Valentini, Nesci, S., Papola, F., Scatena, Mariotti, Perrone, Laurenti, Grammatico, Paola, Mariani, M., Favoino, B., Guizzardi, Pontiero, Leoni, P., Rambaldi, A., Casini, M., Angelucci, E., Baronciani, D., La Nasa, G., Milone, G., Guidi, S., Van Lint, M. T., Dini, G., Corradini, P., Milani, R., Morra, E., Marenco, P., Deliliers, Lambretenghi G., Onida, F., Marcatti, M., Castagna, L., Pioltelli, P., Selleri, C., Zanesco, L., Scime, R., Musso, M., Alessandrino, E. P., Locatelli, F., Visani, G., Di Bartolomeo, P., Papineschi, F., Favre, C., Iori, A. P., Foa, Roberto, Locasciulli, A., Majolino, I., Majolino, P., Leone, G., Arcese, W., Cerretti, R., Carella, A. M., Cascavilla, N., Lauria, F., Mazza, P., Cerno, M., Benedetti, F., Crocchiolo, R, Zino, E, Vago, L, Oneto, R, Bruno, B, Pollichieni, S, Sacchi, N, Sormani, Mp, Marcon, J, Lamparelli, T, Fanin, R, Garbarino, L, Miotti, V, Bandini, G, Bosi, A, Ciceri, F, Bacigalupo, A, and Fleischhauer, K

Subjects
Adult, Disease-Free Survival, Donor Selection, Female, HLA-DRB1 Chains, Hematologic Neoplasms, Humans, Italy, Male, Middle Aged, Recurrence, Registries, Retrospective Studies, Risk Factors, Survival Rate, Transplantation, Homologous, Algorithms, HLA-DR Antigens, Hematopoietic Stem Cell Transplantation, Tissue Donors, Biochemistry, Immunology, Hematology, Cell Biology, Homologous, medicine.medical_treatment, Human leukocyte antigen, Hematopoietic stem cell transplantation, Medicine, Risk factor, Survival rate, Transplantation, HLA-DPB1, business.industry, Hazard ratio, Confidence interval, business, Settore MED/15 - Malattie del Sangue
Abstract

The importance of donor-recipient human leukocyte antigen (HLA)-DPB1 matching for the clinical outcome of unrelated hematopoietic stem cell transplantation (HSCT) is controversial. We have previously described an algorithm for nonpermissive HLA-DPB1 disparities involving HLA-DPB1*0901,*1001,*1701,*0301,*1401,*4501, based on T-cell alloreactivity patterns. By revisiting the immunogenicity of HLA-DPB1*02, a modified algorithm was developed and retrospectively tested in 621 unrelated HSCTs facilitated through the Italian Registry for onco-hematologic adult patients. The modified algorithm proved to be markedly more predictive of outcome than the original one, with significantly higher KaplanMeier probabilities of 2-year survival in permissive compared with nonpermissive transplantations (55% vs 39%, P = .005). This was the result of increased adjusted hazards of nonrelapse mortality (hazard ratio [HR] = 1.74; confidence interval [CI], 1.19-2.53; P = .004) but not of relapse (HR = 1.02; CI, 0.73-1.42; P = .92). The increase in the hazards of overall mortality by nonpermissive HLA-DPB1 disparity was similar in 10 of 10 (HR = 2.12; CI, 1.23-3.64; P = .006) and 9 of 10 allele-matched transplantations (HR = 2.21; CI, 1.28-3.80; P = .004), both in early-stage and in advanced-stage disease. These data call for revisiting current HLA matching strategies for unrelated HSCT, suggesting that searches should be directed up-front toward identification of HLA-DPB1 permissive, 10 of 10 or 9 of 10 matched donors. (Blood. 2009; 114:1437-1444) RI Porfirio, Berardino/I-1988-2012

Published
2009

32. Allotransplant after autologous haematopoietic stem cell transplantation relapse in aggressive lymphoma patients: update af a retrospective GITMO study

Author

Rigacci L, Bosi A, Puccini B, Corradini P, Castagna L, Cascavilla N, Milone G, Bacigalupo A, Scime R, Specchia G, Rambaldi A, Leoni P, Levis A, Guidi S, Bruno B, Oneto R, Fanin R., CICERI , FABIO, Rigacci, L, Bosi, A, Puccini, B, Corradini, P, Castagna, L, Cascavilla, N, Milone, G, Bacigalupo, A, Scime, R, Specchia, G, Rambaldi, A, Leoni, P, Ciceri, Fabio, Levis, A, Guidi, S, Bruno, B, Oneto, R, and Fanin, R.

Published
2009

33. Non-permissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation

Author

Crocchiolo R, Zino E, Vago L, Oneto R, Bruno B, Pollicchieni S, Sacchi N, Sormani MP, Marcon J, Fanin R, Garbarino L, Miotti V, Bandini G, Bosi A, Bacigalupo A, Fleischhauer K., CICERI , FABIO, Crocchiolo, R, Zino, E, Vago, L, Oneto, R, Bruno, B, Pollicchieni, S, Sacchi, N, Sormani, Mp, Marcon, J, Fanin, R, Garbarino, L, Miotti, V, Bandini, G, Bosi, A, Ciceri, Fabio, Bacigalupo, A, and Fleischhauer, K.

Published
2009

35. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Author

Alessandrino, Ep, Porta, Mg, Malcovati, L, Jackson, Ch, Pascutto, C, Bacigalupo, A, Teresa van Lint, M, Falda, M, Bernardi, M, Onida, F, Guidi, S, Iori, Ap, Cerretti, R, Marenco, P, Pioltelli, P, Angelucci, E, Oneto, R, Ripamonti, F, Rambaldi, A, Bosi, A, Cazzola, M, Gruppo Italiano Trapianto di Midollo Osseo Levis, A, Bandini, G, Casini, M, Rossi, G, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Van Lint MT, Corradini, P, Milani, R, Morra, E, Lambertenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scime, R, Iannitto, E, Musso, M, Locatelli, F, Zecca, M, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, Federico, Messina, G, Merli, F, Foa, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, B, Boccadoro, M, Fanin, R, Cerno, M, Bortolo, S, and Author information, Raimondi R.

Subjects
Oncology, Adolescent, Adult, Aged, Aged, 80 and over, Child, Cohort Studies, Female, Humans, Male, Markov Chains, Middle Aged, Myelodysplastic Syndromes, Risk, Survival Analysis, Time Factors, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation, Hematology, Homologous, medicine.medical_specialty, Allogeneic transplantation, medicine.medical_treatment, Hematopoietic stem cell transplantation, Natural history of disease, Internal medicine, medicine, 80 and over, Survival analysis, Transplantation, business.industry, Myelodysplastic syndromes, Original Articles, medicine.disease, Settore MED/15, Surgery, allogeneic transplantation, International Prognostic Scoring System, Risk assessment, business
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Registry studies have shown that advanced disease stage at transplantation is associated with inferior overall survival. To define the optimal timing of allogeneic HSCT, we carried out a decision analysis by studying 660 patients who received best supportive care and 449 subjects who underwent transplantation. Risk assessment was based on both the International Prognostic Scoring System (IPSS) and the World Health Organization classification-based Prognostic Scoring System (WPSS). We used a continuous-time multistate Markov model to describe the natural history of disease and evaluate the effect of allogeneic HSCT on survival. This model estimated life expectancy from diagnosis according to treatment policy at different risk stages. Relative to supportive care, estimated life expectancy increased when transplantation was delayed from the initial stages until progression to intermediate-1 IPSS-risk or to intermediate WPSS-risk stage, and then decreased for higher risks. Modeling decision analysis on WPSS versus IPSS allowed better estimation of the optimal timing of transplantation. These observations indicate that allogeneic HSCT offers optimal survival benefits when the procedure is performed before MDS patients progress to advanced disease stages. Am. J. Hematol. 88:581–588, 2013. © 2013 Wiley Periodicals, Inc.

Published
2013

37. Fludarabine, cyclophosphamide, anti-thymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia (SAA): a retrospective study from the EBMT-SAA Working Party

Author

Bacigalupo, A, Socie', G, Lanino, E, Prete, A, Locatelli, F, Locasciulli, A, Cesaro, Simone, Shimoni, A, Marsh, J, Brune, M, van Lint MT, Oneto, R, and Passweg, J.

Subjects
Thymocyte globulin, alternative donor transplants, severe aplastic anemia
Published
2010

38. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation

Author

Crocchiolo, R, Zino, E, Vago, L, Oneto, R, Bruno, B, Pollichieni, S, Sacchi, N, Sormani, Mp, Marcon, J, Lamparelli, T, Fanin, R, Garbarino, L, Miotti, V, Bandini, G, Bosi, A, Ciceri, F, Bacigalupo, A, Fleischhauer, K, Gruppo Italiano Trapianto di Midollo Osseo, Terapia Cellulare, Cellule Staminale Ematopoietiche e., Italian Bone Marrow Donor Registry, Scalari, P, Bontempelli, M, Prinoth, O, Carcassi, C, Marcenò, R, Porfirio, Rombolà, G, Lombardo, Ferrioli, G, Poli, F, Scalamogna, M, Mazzi, B, Rossi, F, Mascaretti, L, Albergoni, Salvaneschi, L, Martinetti, M, Valentini, Renzo, Nesci, S, Papola, F, Scatena, Mariotti, Perrone, Laurenti, Grammatico, P, Mariani, M, Favoino, B, Guizzardi, Pontiero, Leoni, P, Rambaldi, A, Casini, M, Angelucci, E, Baronciani, D, La Nasa, G, Milone, G, Guidi, S, Van Lint MT, Dini, G, Corradini, P, Milani, R, Morra, E, Marenco, P, Lambretenghi Deliliers, G, Onida, F, Marcatti, M, Castagna, L, Pioltelli, P, Selleri, C, Zanesco, L, Scimè, R, Musso, M, Alessandrino, Ep, Locatelli, F, Visani, G, Di Bartolomeo, P, Papineschi, Federico, Favre, C, Iori, Ap, Foà, R, Locasciulli, A, Majolino, I, Majolino, P, Leone, G, Arcese, W, Cerretti, R, Carella, Am, Cascavilla, N, Lauria, F, Mazza, P, Cerno, M, and Benedetti, F.

Published
2009

39. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome : a study from the Gruppo Italiano Trapianto di Midollo Osseo(GITMO)

Author

Alessandrino, Ep, Della Porta MG, Bacigalupo, A, Van Lint MT, Falda, M, Onida, F, Bernardi, M, Iori, Ap, Rambaldi, A, Cerretti, R, Marenco, P, Pioltelli, P, Malcovati, L, Pascutto, C, Oneto, R, Fanin, R, Bosi, A, Collaboratori Levis, A, Bandini, G, Casini, M, Rossi, G, Angelucci, E, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Guidi, S, Corradini, P, Milani, R, Morra, E, Lambretenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scimè, R, Iannitto, E, Musso, M, Locatelli, F, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, F, Messina, G, Gugliotta, L, Foà, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, Benedetto, Boccadoro, Mario, Cerno, M, and Raimondi, R.

Subjects
Adult, Male, medicine.medical_specialty, Blood transfusion, Adolescent, medicine.medical_treatment, Immunology, World Health Organization, Biochemistry, Gastroenterology, Humans, Myelodysplastic Syndromes, Prognosis, Aged, Recurrence, Survival Rate, Classification, Blood Transfusion, Hematopoietic Stem Cell Transplantation, Middle Aged, Female, Refractory, hemic and lymphatic diseases, Internal medicine, medicine, Survival rate, Acute leukemia, Hematology, business.industry, Cancer, Cell Biology, medicine.disease, Surgery, Transplantation, Who classification, business, Settore MED/15 - Malattie del Sangue
Abstract

We evaluated the impact of World Health Organization (WHO) classification and WHO classification–based Prognostic Scoring System (WPSS) on the outcome of patients with myelodysplastic syndrome (MDS) who underwent allogeneic stem cell transplantation (allo-SCT) between 1990 and 2006. Five-year overall survival (OS) was 80% in refractory anemias, 57% in refractory cytopenias, 51% in refractory anemia with excess blasts 1 (RAEB-1), 28% in RAEB-2, and 25% in acute leukemia from MDS (P = .001). Five-year probability of relapse was 9%, 22%, 24%, 56%, and 53%, respectively (P < .001). Five-year transplant-related mortality (TRM) was 14%, 39%, 38%, 34%, and 44%, respectively (P = .24). In multivariate analysis, WHO classification showed a significant effect on OS (P = .017) and probability of relapse (P = .01); transfusion dependency was associated with a reduced OS (P = .01) and increased TRM (P = .037), whereas WPSS showed a prognostic significance on both OS (P = .001) and probability of relapse (P < .001). In patients without excess blasts, multilineage dysplasia and transfusion dependency affected OS (P = .001 and P = .009, respectively), and were associated with an increased TRM (P = .013 and P = .031, respectively). In these patients, WPSS identified 2 groups with different OS and TRM. These data suggest that WHO classification and WPSS have a relevant prognostic value in posttransplantation outcome of MDS patients.

Published
2008

40. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Author

Alessandrino, Ep, Della Porta MG, Bacigalupo, A, Van Lint MT, Falda, M, Onida, F, Bernardi, M, Iori, Ap, Rambaldi, A, Cerretti, R, Marenco, P, Pioltelli, P, Malcovati, L, Pascutto, C, Oneto, R, Fanin, R, Bosi, A, Gruppo Italiano Trapianto di Midollo Osseo, Levis, A, Bandini, G, Casini, M, Rossi, G, Angelucci, E, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Guidi, S, Corradini, P, Milani, R, Morra, E, Lambretenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scimè, R, Iannitto, E, Musso, M, Locatelli, F, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, Federico, Messina, G, Gugliotta, L, Foà, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, B, Boccadoro, M, Cerno, M, and Raimondi, R.

Published
2008

42. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Dufour, C., primary, Pillon, M., additional, Passweg, J., additional, Socie, G., additional, Bacigalupo, A., additional, Franceschetto, G., additional, Carraro, E., additional, Oneto, R., additional, Risitano, A. M., additional, de Latour, R. P., additional, Tichelli, A., additional, Rovo, A., additional, Peters, C., additional, Hoechsmann, B., additional, Samarasinghe, S., additional, Kulasekararaj, A. G., additional, Schrezenmeier, H., additional, Aljurf, M., additional, and Marsh, J., additional

Published
2014
Full Text
View/download PDF

44. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation

Author

Martínez, C, Canals, C, Sarina, B, Alessandrino, Ep, Karakasis, D, Pulsoni, A, Sica, Simona, Trneny, M, Snowden, Ja, Kanfer, E, Milpied, N, Bosi, A, Guidi, S, De Souza, Ca, Willemze, R, Arranz, R, Jebavy, L, Hellmann, A, Sibon, D, Oneto, R, Luan, Jj, Dreger, P, Castagna, L, Sureda, A., Sica, Simona (ORCID:0000-0003-2426-3465), Martínez, C, Canals, C, Sarina, B, Alessandrino, Ep, Karakasis, D, Pulsoni, A, Sica, Simona, Trneny, M, Snowden, Ja, Kanfer, E, Milpied, N, Bosi, A, Guidi, S, De Souza, Ca, Willemze, R, Arranz, R, Jebavy, L, Hellmann, A, Sibon, D, Oneto, R, Luan, Jj, Dreger, P, Castagna, L, Sureda, A., and Sica, Simona (ORCID:0000-0003-2426-3465)

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for patients with relapsed Hodgkin's lymphoma (HL). However, there is currently little information on the predictors of outcome for patients whose disease recurs after ASCT.

Published
2013

46. Current Outcome Of HLA Identical Sibling Vs Unrelated DONOR Transplants In Severe Aplastic Anemia : An EBMT Analysis

Author

Bacigalupo, Andrea, primary, Socié, Gérard, additional, Hamljadi, Rose-Marie, additional, Aljurf, Mahmoud, additional, Mashan, A, additional, Kyrcz-Krzemien, Slawomira, additional, Cybicka, A, additional, Sengeloev, H, additional, Unal, Ali, additional, Beelen, Dietrich, additional, Locasciulli, A, additional, Dufour, Carlo, additional, Passweg, Jakob R., additional, Oneto, R, additional, and Marsh, Judith, additional

Published
2013
Full Text
View/download PDF

47. Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation

Author

Gerull, S., primary, Stern, M., additional, Apperley, J., additional, Beelen, D., additional, Brinch, L., additional, Bunjes, D., additional, Butler, A., additional, Ganser, A., additional, Ghavamzadeh, A., additional, Koh, M. B., additional, Komarnicki, M., additional, Kroger, N., additional, Maertens, J., additional, Maschan, A., additional, Peters, C., additional, Rovira, M., additional, Sengelov, H., additional, Socie, G., additional, Tischer, J., additional, Oneto, R., additional, Passweg, J., additional, and Marsh, J., additional

Published
2013
Full Text
View/download PDF

48. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia.

Author

Schrezenmeier, H., Passweg, J.R., Marsh, J.C., Bacigalupo, A., Bredeson, C.N., Bullorsky, E., Camitta, B.M., Champlin, R.E., Gale, R.P., Fuhrer, M., Klein, J.P., Locasciulli, A., Oneto, R., Schattenberg, A.V.M.B., Socie, G., Eapen, M., Schrezenmeier, H., Passweg, J.R., Marsh, J.C., Bacigalupo, A., Bredeson, C.N., Bullorsky, E., Camitta, B.M., Champlin, R.E., Gale, R.P., Fuhrer, M., Klein, J.P., Locasciulli, A., Oneto, R., Schattenberg, A.V.M.B., Socie, G., and Eapen, M.

Abstract

Contains fulltext : 52067schattenberg.pdf (publisher's version ) (Closed access), We analyzed the outcome of 692 patients with severe aplastic anemia (SAA) receiving transplants from HLA-matched siblings. A total of 134 grafts were peripheral blood progenitor cell (PBPC) grafts, and 558 were bone marrow (BM) grafts. Rates of hematopoietic recovery and grades 2 to 4 chronic graft-versus-host disease (GVHD) were similar after PBPC and BM transplantations regardless of age at transplantation. In patients older than 20 years, chronic GVHD and overall mortality rates were similar after PBPC and BM transplantations. In patients younger than 20 years, rates of chronic GVHD (relative risk [RR] 2.82; P = .002) and overall mortality (RR 2.04; P = .024) were higher after transplantation of PBPCs than after transplantation of BM. In younger patients, the 5-year probabilities of overall survival were 73% and 85% after PBPC and BM transplantations, respectively. Corresponding probabilities for older patients were 52% and 64%. These data indicate that BM grafts are preferred to PBPC grafts in young patients undergoing HLA-matched sibling donor transplantation for SAA.

Published
2007

49. A boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation

Author

Larocca, A, Piaggio, G, Podestà, M, Pitto, A, Bruno, B, Di Grazia, C, Gualandi, F, Occhini, D, Raiola, A, Dominietto, A, Bregante, S, Lamparelli, T, Tedone, E, Oneto, R, Frassoni, F, Van Lint, M, Pogliani, E, Bacigalupo, A, Raiola, AM, Van Lint, MT, POGLIANI, ENRICO MARIA, BACIGALUPO, ANITA, Larocca, A, Piaggio, G, Podestà, M, Pitto, A, Bruno, B, Di Grazia, C, Gualandi, F, Occhini, D, Raiola, A, Dominietto, A, Bregante, S, Lamparelli, T, Tedone, E, Oneto, R, Frassoni, F, Van Lint, M, Pogliani, E, Bacigalupo, A, Raiola, AM, Van Lint, MT, POGLIANI, ENRICO MARIA, and BACIGALUPO, ANITA

Abstract

Background and Objectives. A proportion of patients develop poor graft function (PGF) following an allogeneic hemopoietic stem cell transplant (HSCT). It is uncertain whether a boost of donor marrow or blood cells is beneficial in terms of trilineage recovery and nonrelapse-related mortality (NRM). Design and Methods. The aim of this study was to compare outcomes in patients with PGF and full donor chimerism following an allogeneic HSCT who did or did not receive a boost of donor stem cells. The study included patients with primary PGF - i.e. those failing to achieve sustained graft function- and secondary PGF - i.e. those developing PGF after complete hematologic recovery. We studied 54 patients with PGF: 20 patients received no further donor cell infusion (group A), 14 received a boost of unmanipulated marrow or blood cells from the original donor, without further conditioning (group B), and 20 received donor cells after CD34 selection without conditioning (group C). The three groups were comparable for disease phase, patients' age, donor type, primary or secondary PGF, full donor chimerism and duration of PGF. Results. Trilineage recovery was seen in 40%, 36% and 75% of the patients in, respectively, groups A, B and C (p=0.02). In multivariate Cox analysis trilineage recovery was more frequent in patients with secondary PGF (RR of complete recovery 2.82, p=0.01) and in patients receiving CD34(+)-selected cells (RR of complete recovery 3.0; p=0.007). There was no effect of donor type on hematologic recovery. The rate of NRM was 55%, 64%, 20% in groups A, B and C, respectively (p=0.06) and was highly correlated with trilineage recovery (RR 0.36, p < 0.0001). PGF was the primary cause of death in 30%, 21% and 10% of the patients in the three groups, graft-versus-host disease (GVHD) in 5%, 36%, and 10%. Interpretations and Conclusions. In patients with poor graft function (a) a boost of CD34(+)-selected peripheral blood donor cells is associated with a high chance of

Published
2006

50. Haematopoietic stem cell transplantation for Shwachman-Diamond disease: a study from the European Group for blood and marrow transplantation

Author

UCL - MD/GYPE - Département de gynécologie, d'obstétrique et de pédiatrie, Cesaro, S, Oneto, R, Messina, C, Gibson, BE, Buzyn, A., Steward, C, Gluckman, E., Breddius, R, Boogaerts, M., Vermylen, Christiane, Veys, P, Marsh, J, Badell, I, Michel, G, Gungor, T, Niethammer, D, Bordigoni, P., Oswald, C, Favre, C, Passweg, J, Dini, G, UCL - MD/GYPE - Département de gynécologie, d'obstétrique et de pédiatrie, Cesaro, S, Oneto, R, Messina, C, Gibson, BE, Buzyn, A., Steward, C, Gluckman, E., Breddius, R, Boogaerts, M., Vermylen, Christiane, Veys, P, Marsh, J, Badell, I, Michel, G, Gungor, T, Niethammer, D, Bordigoni, P., Oswald, C, Favre, C, Passweg, J, and Dini, G

Abstract

This report assessed the results of allogeneic stem cell transplantation (allo-SCT) in 26 patients with Shwachman-Diamond disease (SDS) and severe bone marrow abnormalities. The conditioning regimen was based on busulphan (54%), total body irradiation (23%), fludarabine (15%) or other chemotherapy combinations (8%). Standard prevention of graft versus host disease (GVHD) with ciclosporin +/- methotrexate was adopted in 54% of the patients whilst in vivo or in vitro T-cell depletion was used in 17 and four patients respectively. Neutrophil and platelet engraftment were achieved in 21 (81%) and 17 (65%) of 26 patients after a median time of 18 days and 29 days respectively. The incidence of grade III and IV acute GVHD was 24% and of chronic GVHD 29%. Nine patients died after a median time of 70 d, post-SCT. After a median follow-up of 1.1 years, the transplant-related mortality was 35.5% (95% CI 17-54) whilst the overall survival was 64.5% (95% CI 45.7-83.2). Allo-SCT was found to be successful in more than half of SDS patients with severe bone marrow dysfunction. Further improvements would be anticipated by a better definition of the optimum time in the course of disease to transplant and by the adoption of less toxic conditioning regimens.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results